1. Home
  2. GGR vs IFRX Comparison

GGR vs IFRX Comparison

Compare GGR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gogoro Inc.

GGR

Gogoro Inc.

HOLD

Current Price

$3.21

Market Cap

88.6M

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.20

Market Cap

71.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGR
IFRX
Founded
2011
2007
Country
Taiwan
Germany
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
88.6M
71.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
GGR
IFRX
Price
$3.21
$1.20
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
21.6K
658.1K
Earning Date
02-12-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$280,211,000.00
$73,729.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.15
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.72
$0.71
52 Week High
$10.15
$2.77

Technical Indicators

Market Signals
Indicator
GGR
IFRX
Relative Strength Index (RSI) 41.98 57.33
Support Level $2.96 $0.99
Resistance Level $3.20 $1.16
Average True Range (ATR) 0.23 0.08
MACD -0.04 0.02
Stochastic Oscillator 42.72 89.13

Price Performance

Historical Comparison
GGR
IFRX

About GGR Gogoro Inc.

Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: